American Journal of Cardiology
Volume 102, Issue 9 , Pages 1151-1155 , 1 November 2008

Usefulness of Proteinuria as a Prognostic Marker of Mortality and Cardiovascular Events Among Patients Undergoing Percutaneous Coronary Intervention (Data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial)

  • Nestor Mercado, MD, PhD

      Affiliations

    • Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California
    • ,
  • Jasper J. Brugts, MD, MSc

      Affiliations

    • Department of Interventional Cardiology and Clinical Epidemiology Unit, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel: +31-10-703-1528; Fax: +31-10-703-2890
    • ,
  • Joachim H. Ix, MD, MAS

      Affiliations

    • Department of Medicine, Division of Nephrology, University of California, San Francisco, California
    • ,
  • Michael G. Shlipak, MD, MPH

      Affiliations

    • Department of Interventional Cardiology and Clinical Epidemiology Unit, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    • Department of Epidemiology, University of California, San Francisco, California
    • Department of Biostatistics, University of California, San Francisco, California
    • Section of General Internal Medicine, VA Medical Center, San Francisco, California
    • ,
  • Simon R. Dixon, MBChB

      Affiliations

    • Division of Cardiology, William Beaumont Hospital, Royal Oak, Michigan
    • ,
  • Bernard J. Gersh, MBChB, DPhil

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
    • ,
  • Pedro A. Lemos, MD, PhD

      Affiliations

    • Heart Institute, University of Sao Paulo Medical School, Sao Paulo, Brazil
    • ,
  • Mimi Guarneri, MD

      Affiliations

    • Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California
    • ,
  • Paul S. Teirstein, MD

      Affiliations

    • Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California
    • ,
  • William Wijns, MD, PhD

      Affiliations

    • Cardiovascular Center, O.L.V. Hospital, Aalst, Belgium
    • ,
  • Patrick W. Serruys, MD, PhD

      Affiliations

    • Department of Interventional Cardiology and Clinical Epidemiology Unit, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • Eric Boersma, PhD

      Affiliations

    • Department of Interventional Cardiology and Clinical Epidemiology Unit, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands
    • ,
  • William W. O'Neill, MD

      Affiliations

    • Leonard M. Miller School of Medicine, University of Miami, Miami, Florida

Received 15 April 2008 ,Revised 11 June 2008 ,Accepted 11 June 2008.

References 

  1. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization (EXCITE Trial Investigators. Evaluation of Oral xemilofiban in Controlling Thrombotic Events). N Engl J Med. 2000;342:1316–1324
  2. Kim MS, Corwin HL. Urinalysis. In:  Schrier RW editors. Diseases of the Kidney and Urinary Tract. 8th Ed.. Philadelphia: Lippincott Williams & Wilkins; 2007;p. 286–298
  3. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  4. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl):S1–S266
  5. Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol. 1998;9:2157–2169
  6. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319–323
  7. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994;344:14–18
  8. Brugts JJ, Knetsch AMK, Mattace-Raso FUS, Hofman A, Witteman JCM. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch Intern Med. 2005;165:2659–2665
  9. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103:1869–1874
  10. Cosson E, Pham I, Valensi P, Paries J, Attali JR, Nitenberg A. Impaired coronary endothelium-dependent vasodilation is associated with microalbuminuria in patients with type 2 diabetes and angiographically normal coronary arteries. Diabetes Care. 2006;29:107–112
  11. Berton G, Cordian RO, Palmieri R, Cucchini F, de Toni R, Palatini P. Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortality. Eur Heart J. 2001;22:1466–1475
  12. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  13. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–1782
  14. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139:901–906
  15. Marso SP, Ellis SG, Tuzcu M, Whitlow PL, Franco I, Raymond RE, et al. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics. J Am Coll Cardiol. 1999;33:1269–1277
  16. Reeder GS, Holmes DR, Lennon RJ, Larson TS, Frye RL. Proteinuria, serum creatinine, and outcome of percutaneous coronary intervention in patients with diabetes mellitus. Am J Cardiol. 2002;89:760–764
  17. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint Reduction In Hypertension Study. Hypertension. 2005;45:198–202
  18. Ix JH, Shlipak MG, Chertow GM, Ali S, Schiller NB, Whooley MA. Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study. J Card Fail. 2006;12:601–607
  19. Bruch C, Rothenburger M, Gotzmann M, Wichter T, Scheld HH, Breithardt G, et al. Chronic kidney disease in patients with chronic heart failure—impact on intracardiac conduction, diastolic function and prognosis. Int J Cardiol. 2007;118:375–380

PII: S0002-9149(08)01137-5

doi: 10.1016/j.amjcard.2008.06.035

American Journal of Cardiology
Volume 102, Issue 9 , Pages 1151-1155 , 1 November 2008

Article Tools

* Image Usage & Resolution